Natalizumab is a humanized monoclonal antibody directed against Very Late Activation Antigene 4 (VLA-4) and has a potent effect on disease activity in multiple sclerosis (MS). A blockade of VLA-4 with natalizumab may not only interfere with autoimmunological processes but also with central nervous system (CNS) immune surveillance.
Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cells (Tregs).
Study Type
OBSERVATIONAL
Enrollment
27
Function of T regulatory cells
Time frame: at month 3
Change in distinct immune cell lines
Time frame: month 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.